ERBB2 and pneumonitis: Since HER2 inhibition alone is not associated with a significant risk for pneumonitis [4, 34], and the risk for pneumonitis is much lower with other ADC payloads [35, 36], it is likely that the deruxtecan portion of T-DXd primarily contributes to the risk for pneumonitis.